IDEAYA Biosciences(IDYA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IDYA IDEAYA Biosciences

盘后交易 03-05 17:00:50 EST

33.03

-1.65

-4.76%

盘后33.36

+0.33+1.00%

16:27 EST

最高34.19	最低32.88	成交量66.47万
今开34.13	昨收34.68	日振幅3.78%
总市值28.96亿	流通市值27.02亿	总股本8,767万
成交额2,210万	换手率0.81%	流通股本8,182万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IDYA","market":"US","secType":"STK","nameCN":"IDEAYA Biosciences","latestPrice":33.03,"timestamp":1772744400000,"preClose":34.68,"halted":0,"volume":664657,"hourTrading":{"tag":"盘后","latestPrice":33.36,"preClose":33.03,"latestTime":"16:27 EST","volume":9342,"amount":308566.56828600005,"timestamp":1772746063714,"change":0.33,"changeRate":0.009991,"amplitude":0.009991},"delay":0,"changeRate":-0.047577854671280236,"floatShares":81816082,"shares":87666408,"eps":-1.284937,"marketStatus":"盘后交易","change":-1.65,"latestTime":"03-05 17:00:50 EST","open":34.13,"high":34.19,"low":32.8801,"amount":22098881.49735,"amplitude":0.037771,"askPrice":33.68,"askSize":59,"bidPrice":33,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-1.284937,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1772758800000},"marketStatusCode":4,"adr":0,"listingDate":1558584000000,"exchange":"NASDAQ","adjPreClose":34.68,"preHourTrading":{"tag":"盘前","latestPrice":34.26,"preClose":34.68,"latestTime":"09:29 EST","volume":641,"amount":22283.868225000002,"timestamp":1772720999967,"change":-0.42,"changeRate":-0.012111,"amplitude":0.018454},"postHourTrading":{"tag":"盘后","latestPrice":33.36,"preClose":33.03,"latestTime":"16:27 EST","volume":9342,"amount":308566.56828600005,"timestamp":1772746063714,"change":0.33,"changeRate":0.009991,"amplitude":0.009991},"volumeRatio":0.648913,"optionData":{"bulkOrders":[{"symbol":"IDYA","call":true,"expireDate":1776398400000,"strike":"45.0","timestamp":1772735286072,"price":1.97,"volume":5000,"amount":985000,"type":"-"},{"symbol":"IDYA","call":false,"expireDate":1776398400000,"strike":"22.5","timestamp":1772735286072,"price":2.27,"volume":5000,"amount":1135000,"type":"+"}]},"impliedVol":1.3936,"impliedVolPercentile":0.9721},"requestUrl":"/m/hq/s/IDYA","defaultTab":"news","newsList":[{"id":"2614511540","title":"IDEAYA生物科学公司开始针对B7H3和PTK7的IDE034一期临床试验，用于晚期实体瘤IDEAYA Biosciences Begins Phase 1 Trial of IDE034 Targeting B7H3 and PTK7 in Advanced Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2614511540","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614511540?lang=zh_cn&edition=full","pubTime":"2026-02-25 20:07","pubTimestamp":1772021220,"startTime":"0","endTime":"0","summary":"IDE034 is described as a potential first-in-class ADC that incorporates a topoisomerase I inhibitor payload..IDE034被描述为一种潜在的同类首个ADC，它包含拓扑异构酶I抑制剂有效载荷。The Phase 1 trial aims to assess IDE034 in patients with advanced solid tumors. According to the announcement, the drug’s dual-targeting mechanism focuses on B7H3 and PTK7, two proteins associated with tumor growth and progression. This approach seeks to enhance therapeutic precision while minimizing off-target effects.一期试验旨在评估IDE034在晚期实体瘤患者中的效果。根据公告，该药物的双重靶向机制聚焦于B7H3和PTK7，这两种与肿瘤生长和进展相关的蛋白质。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225201021a4c73b9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260225201021a4c73b9c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IDYA","BK4139"],"gpt_icon":0},{"id":"1191218960","title":"IDEAYA Biosciences宣布启动Ide034一期临床试验首位患者入组，该药物有望成为同类首创B7h3/Ptk7双特异性Top1 ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=1191218960","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191218960?lang=zh_cn&edition=full","pubTime":"2026-02-25 19:06","pubTimestamp":1772017617,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences宣布，其创新药物Ide034的一期临床试验已完成首位患者入组。该候选药物作为靶向B7h3和Ptk7的双特异性拓扑异构酶1（Top1）抗体偶联药物（ADC），具备成为同类首创疗法的潜力。\n此次临床试验的启动标志着IDEAYA在精准肿瘤治疗领域取得重要进展。Ide034独特的作用机制有望为特定癌症患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"gpt_icon":0},{"id":"1194916310","title":"IDEAYA Biosciences任命医学博士、哲学博士Theodora (Theo) Ross为首席开发官","url":"https://stock-news.laohu8.com/highlight/detail?id=1194916310","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194916310?lang=zh_cn&edition=full","pubTime":"2026-02-23 19:00","pubTimestamp":1771844413,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences宣布，正式委任医学博士、哲学博士Theodora（Theo）Ross担任公司首席开发官一职。此次任命将进一步加强公司在肿瘤靶向治疗领域的研发领导力，为推进创新疗法管线注入关键专业力量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"gpt_icon":0},{"id":"2613724942","title":"IDEAYA生物科学2025财年实现净利润-1.14亿美元，同比增加58.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613724942","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613724942?lang=zh_cn&edition=full","pubTime":"2026-02-21 00:00","pubTimestamp":1771603232,"startTime":"0","endTime":"0","summary":"2月21日，IDEAYA生物科学公布财报，公告显示公司2025财年净利润为-1.14亿美元，同比增加58.39%；其中营业收入为2.19亿美元，同比增加3028.57%，每股基本收益为-1.28美元。从资产负债表来看，IDEAYA生物科学总负债86.39百万美元，其中短期债务339000.00美元，资产负债比为0.13，流动比率为0.12。机构评级：截至2026年2月21日，当前有17家机构对IDEAYA生物科学目标价做出预测，其中目标均价为50.76美元，其中最低目标价为31.00美元，最高目标价为79.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260221000044a4b6dff8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260221000044a4b6dff8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IDYA","BK4023","PARG"],"gpt_icon":0},{"id":"1121477248","title":"IDEAYA Biosciences预计2026年底前公布IDE849全球一期临床试验初步数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1121477248","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121477248?lang=zh_cn&edition=full","pubTime":"2026-02-17 19:04","pubTimestamp":1771326251,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences（股票代码：IDYA）宣布，由其主导的IDE849全球一期临床试验的初步临床数据更新，预计将在2026年底前发布。该试验旨在评估IDE849在患者中的安全性和有效性，为后续开发提供关键依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"gpt_icon":0},{"id":"1101509523","title":"IDEAYA Biosciences 公布2025年第四季度及全年财务业绩并更新业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1101509523","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101509523?lang=zh_cn&edition=full","pubTime":"2026-02-17 19:01","pubTimestamp":1771326074,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences 已正式发布其2025年第四季度及全年的财务报告，同时向市场通报了最新的业务动态。此次披露涵盖公司关键财务指标与研发管线的重要进展，为投资者提供了全面的运营概览。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"gpt_icon":0},{"id":"2608718758","title":"IDEAYA生物科学盘中异动 早盘快速拉升5.03%报33.81美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608718758","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608718758?lang=zh_cn&edition=full","pubTime":"2026-02-02 22:58","pubTimestamp":1770044325,"startTime":"0","endTime":"0","summary":"北京时间2026年02月02日22时58分，IDEAYA生物科学股票出现波动，股价快速拉升5.03%。截至发稿，该股报33.81美元/股，成交量9.1298万股，换手率0.10%，振幅5.03%。IDEAYA生物科学股票所在的生物技术行业中，整体涨幅为0.83%。IDEAYA生物科学公司简介：IDEAYA Biosciences Inc是一家专注于肿瘤学的精准医学公司，致力于发现和开发针对通过分子诊断选择的患者群体的靶向治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202225845a6cac68e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260202225845a6cac68e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4023","BK4139","IDYA","PARG"],"gpt_icon":0},{"id":"1179251871","title":"IDEAYA Biosciences 在第44届摩根大通医疗健康大会上公布业务进展及2026年企业目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1179251871","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179251871?lang=zh_cn&edition=full","pubTime":"2026-01-12 01:01","pubTimestamp":1768150874,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences 于第44届摩根大通医疗健康大会期间，向外界披露了公司最新业务动态。此次更新涵盖了研发管线进展、战略合作态势等关键运营领域。同时，管理层清晰阐述了面向2026年的企业战略目标，为长期发展勾勒出明确路线图。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"gpt_icon":0},{"id":"1166503731","title":"IDEAYA Biosciences完成了一项针对HLA*A2阴性转移性眼黑色素瘤的达罗伐赛替尼与克唑替尼联合治疗的随机关键2/3期试验（Optimum-02）的全面目标入组","url":"https://stock-news.laohu8.com/highlight/detail?id=1166503731","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166503731?lang=zh_cn&edition=full","pubTime":"2025-12-11 19:01","pubTimestamp":1765450873,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences完成了一项针对HLA*A2阴性转移性眼黑色素瘤的达罗伐赛替尼与克唑替尼联合治疗的随机关键2/3期试验（Optimum-02）的全面目标入组。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"gpt_icon":0},{"id":"1184302088","title":"IDEAYA Biosciences 提交 Ide574 的 IND 申请，成为潜在的首个 Kat6/7 双重抑制剂，用于治疗乳腺癌和肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1184302088","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184302088?lang=zh_cn&edition=full","pubTime":"2025-12-10 19:01","pubTimestamp":1765364472,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences 提交 Ide574 的 IND 申请，成为潜在的首个 Kat6/7 双重抑制剂，用于治疗乳腺癌和肺癌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"gpt_icon":0},{"id":"1195525161","title":"IDEAYA Biosciences：12月4日，格拉克索史克终止与IDEAYA Biosciences的合作协议 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1195525161","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195525161?lang=zh_cn&edition=full","pubTime":"2025-12-06 05:24","pubTimestamp":1764969853,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences：12月4日，格拉克索史克终止与IDEAYA Biosciences的合作协议 - SEC备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"gpt_icon":0},{"id":"1152170018","title":"IDEAYA Biosciences宣布获得Ide034的IND批准，成为首个针对多种实体肿瘤类型的双特异性B7h3/Ptk7 Top1抗体药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1152170018","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152170018?lang=zh_cn&edition=full","pubTime":"2025-12-01 19:02","pubTimestamp":1764586929,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences宣布获得Ide034的IND批准，这是一款潜在的首个针对多种实体肿瘤类型的双特异性B7h3/Ptk7 Top1抗体药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"gpt_icon":0},{"id":"1153173463","title":"IDEAYA Biosciences Inc - 截至9月30日拥有约11.4亿美元现金、现金等价物和可出售证券；预计将支持运营至2030年","url":"https://stock-news.laohu8.com/highlight/detail?id=1153173463","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153173463?lang=zh_cn&edition=full","pubTime":"2025-11-04 19:09","pubTimestamp":1762254554,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences Inc - 截至9月30日拥有约11.4亿美元现金、现金等价物和可出售证券；预计将支持运营至2030年","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDYA","BK4139"],"gpt_icon":0},{"id":"1172465068","title":"IDEAYA Biosciences股价上涨2.3%，因其药物组合在罕见眼癌试验中显示生存获益","url":"https://stock-news.laohu8.com/highlight/detail?id=1172465068","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172465068?lang=zh_cn&edition=full","pubTime":"2025-10-20 21:33","pubTimestamp":1760967191,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences股价上涨2.3%，因其药物组合在罕见眼癌试验中显示生存获益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"gpt_icon":0},{"id":"1166166740","title":"IDEAYA Biosciences Inc - 达罗伐西尼与克唑替尼组合展现21.1个月的中位总生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1166166740","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166166740?lang=zh_cn&edition=full","pubTime":"2025-10-20 18:01","pubTimestamp":1760954488,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences Inc - 达罗伐西尼与克唑替尼组合展现21.1个月的中位总生存期","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"gpt_icon":0},{"id":"1168936080","title":"IDEAYA Biosciences宣布其潜在首创Mat2a抑制剂Ide397与Trodelvy®联合治疗Mtap缺失尿路上皮癌的1/2期试验获得积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1168936080","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168936080?lang=zh_cn&edition=full","pubTime":"2025-09-08 20:01","pubTimestamp":1757332875,"startTime":"0","endTime":"0","summary":"IDEAYA Biosciences宣布其潜在首创Mat2a抑制剂Ide397与Trodelvy®联合治疗Mtap缺失尿路上皮癌的1/2期试验获得积极数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IDYA"],"gpt_icon":0},{"id":"2518127182","title":"IDEAYA生物科学盘中异动 股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518127182","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518127182?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:55","pubTimestamp":1741618519,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时55分，IDEAYA生物科学股票出现异动，股价急速跳水5.04%。截至发稿，该股报17.53美元/股，成交量15.5541万股，换手率0.18%，振幅4.71%。IDEAYA生物科学股票所在的生物技术行业中，整体涨幅为0.27%。IDEAYA生物科学公司简介：IDEAYA Biosciences Inc是一家专注于肿瘤学的精准医学公司，致力于发现和开发针对通过分子诊断选择的患者群体的靶向治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022551998a2b17b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022551998a2b17b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PARG","BK4023","BK4139","IDYA"],"gpt_icon":0},{"id":"2516668860","title":"IDEAYA生物科学盘中异动 股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516668860","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516668860?lang=zh_cn&edition=full","pubTime":"2025-03-04 03:55","pubTimestamp":1741031723,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日03时55分，IDEAYA生物科学股票出现波动，股价大幅跳水5.06%。截至发稿，该股报19.53美元/股，成交量36.3073万股，换手率0.41%，振幅7.06%。IDEAYA生物科学股票所在的生物技术行业中，整体涨幅为0.41%。IDEAYA生物科学公司简介：IDEAYA Biosciences Inc是一家专注于肿瘤学的精准医学公司，致力于发现和开发针对通过分子诊断选择的患者群体的靶向治疗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304035523abe68cbd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304035523abe68cbd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IDYA","PARG","BK4023","BK4139"],"gpt_icon":0},{"id":"2512464751","title":"IDEAYA生物科学2024财年实现净利润-2.74亿美元，同比减少142.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512464751","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512464751?lang=zh_cn&edition=full","pubTime":"2025-02-20 12:01","pubTimestamp":1740024073,"startTime":"0","endTime":"0","summary":"2月20日，IDEAYA生物科学公布财报，公告显示公司2024财年净利润为-2.74亿美元，同比减少142.48%；其中营业收入为7.00百万美元，同比减少70.07%，每股基本收益为-3.36美元。从资产负债表来看，IDEAYA生物科学总负债64.94百万美元，其中短期债务298000.00美元，资产负债比为0.18，流动比率为0.15。机构评级：截至2025年2月20日，当前有12家机构对IDEAYA生物科学目标价做出预测，其中目标均价为50.92美元，其中最低目标价为27.00美元，最高目标价为62.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220120114abd5a403&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220120114abd5a403&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IDYA"],"gpt_icon":0},{"id":"2511826524","title":"IDEAYA生物科学盘中异动 股价大跌5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511826524","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511826524?lang=zh_cn&edition=full","pubTime":"2025-02-13 23:26","pubTimestamp":1739460407,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日23时26分，IDEAYA生物科学股票出现波动，股价大幅下跌5.15%。截至发稿，该股报20.82美元/股，成交量14.152万股，换手率0.16%，振幅4.56%。IDEAYA生物科学股票所在的生物技术行业中，整体涨幅为0.15%。IDEAYA生物科学公司简介：IDEAYA Biosciences Inc 是一家专注于肿瘤学的精准医疗公司，致力于发现和开发针对患者群体的靶向治疗方法，使用分子诊断方法进行选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213232647a244b74d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213232647a244b74d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IDYA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ideayabio.com","stockEarnings":[{"period":"1week","weight":0.095},{"period":"1month","weight":0.0182},{"period":"3month","weight":-0.0369},{"period":"6month","weight":0.2769},{"period":"1year","weight":0.8457},{"period":"ytd","weight":0.0032}],"compareEarnings":[{"period":"1week","weight":-0.0116},{"period":"1month","weight":-0.0148},{"period":"3month","weight":0.0011},{"period":"6month","weight":0.0585},{"period":"1year","weight":0.1877},{"period":"ytd","weight":0.0047}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"IDEAYA Biosciences, Inc.总部位于加利福尼亚州南旧金山，于2015年6月在特拉华州注册成立。该公司是一家专注于肿瘤学的精准医学公司，致力于为使用分子诊断选择的患者群体发现和开发靶向疗法。他们的方法将识别和验证翻译生物标志物的广泛能力与小分子药物发现相结合，以选择最有可能从他们正在开发的靶向治疗中受益的患者群体。他们正在将这些能力应用于多类精准医学，包括直接靶向致癌途径和合成致死性，这代表了一类新兴的精准医学靶点。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.019424},{"month":2,"riseRate":0.571429,"avgChangeRate":-0.055936},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.099788},{"month":4,"riseRate":0.5,"avgChangeRate":0.093972},{"month":5,"riseRate":0.5,"avgChangeRate":0.174201},{"month":6,"riseRate":0.714286,"avgChangeRate":0.088034},{"month":7,"riseRate":0.571429,"avgChangeRate":0.026528},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.032458},{"month":9,"riseRate":0.714286,"avgChangeRate":0.113335},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.051627},{"month":11,"riseRate":0.857143,"avgChangeRate":0.118123},{"month":12,"riseRate":0.571429,"avgChangeRate":0.016661}],"exchange":"NASDAQ","name":"IDEAYA Biosciences","nameEN":"IDEAYA Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"IDEAYA Biosciences(IDYA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供IDEAYA Biosciences(IDYA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"IDEAYA Biosciences,IDYA,IDEAYA Biosciences股票,IDEAYA Biosciences股票老虎,IDEAYA Biosciences股票老虎国际,IDEAYA Biosciences行情,IDEAYA Biosciences股票行情,IDEAYA Biosciences股价,IDEAYA Biosciences股市,IDEAYA Biosciences股票价格,IDEAYA Biosciences股票交易,IDEAYA Biosciences股票购买,IDEAYA Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"IDEAYA Biosciences(IDYA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供IDEAYA Biosciences(IDYA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}